The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Full Report Details at
- http://www.fastmr.com/prod/804442_pharmapoint_migraine_us_drug_forecast_and_market.aspx?afid=101
The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan's Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK's Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan.
Scope
* Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in the US from 2012-2023.
* Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market.
Reasons to Get this Report
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Migraine
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2023 in the US
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.2 Symptoms
3.2.1 Premonitory Phase
3.2.2 Aura Phase
3.2.3 Headache Phase
3.2.4 Postdrome Phase
4 Disease Management
4.1 Treatment Overview
4.1.1 Acute Migraine Treatment
4.1.2 Preventive Migraine Treatment
4.2 US
4.2.1 Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles- Major Brands
5.3.1 Triptans
5.3.2 Imitrex (sumatriptan)
5.3.3 Zomig (zolmitriptan)
5.3.4 Amerge (naratriptan)
5.3.5 Maxalt (rizatriptan)
5.3.6 Axert (almotriptan)
5.3.7 Frova (frovatriptan)
5.3.8 Relpax (eletriptan)
5.3.9 Sumavel DosePro (sumatriptan)
5.3.10 Ergot Alkaloids
5.3.11 Beta Blockers
5.3.12 Anti-Epileptics
5.3.13 Antidepressants
5.3.14 Calcium Channel Antagonists
5.3.15 Botox (onabotulinum toxin A)
6 Opportunity and Unmet Need
6.1 Overview
6.1.1 A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
6.1.2 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
6.1.3 Lack of Diagnostic Tools Causes Misdiagnosis
6.1.4 Physician Education
6.1.5 Effective and Well-Tolerated Prophylactic Therapies
6.2 Unmet Needs Gap Analysis
6.2.1 Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
6.2.2 Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
6.2.3 Physician Education
6.2.4 Diagnostic Tools
7 Pipeline Assessment
7.1 Overview
7.2 Promising drugs in clinical development
7.2.1 Zecuity
7.2.2 Levadex
7.2.3 RHB-103
7.2.4 AVP-825
7.2.5 Lasmiditan
7.2.6 MK-1602
7.2.7 SUD-001
7.2.8 RT-001
7.2.9 NXN-188
8 Market Outlook
8.1 US
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Migraine Patients
9.4.2 Percent Drug-treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Survey of Prescribing Physicians
9.7 About the Authors
9.7.1 Author
9.7.2 Reviewer
9.7.3 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer
List of Tables
1.1 List of Tables
Table 1: Classification of Migraine Subtypes
Table 2: Diagnostic Criteria for Migraine with Aura
Table 3: Diagnostic Criteria for Migraine without Aura
Table 4: Treatment Guidelines for Migraine
Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
Table 6: Product Profile - Triptans
Table 7: Triptans SWOT Analysis, 2013
Table 8: Product Profile - Sumavel DosePro
Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=804442&dt=t&afid=101
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
read full article